v3.26.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
Director and Officer Rule 10b5-1 Trading Arrangements
During the fiscal quarter ended September 30, 2026, each of the following officers adopted a Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K). All trading plans are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Name and TitleDateExpiration Date
Maximum Shares Subject to Plan (1)
Christine Fox, EVP, U.S. Commercial
August 4, 2026November 21, 202663,492
Matthew Shields, EVP, Teva Global Operations
August 4, 2026June 5, 2027171,410
Dr. Eric Hughes, EVP, Global R&D and Chief Medical Officer
September 1, 2026March 8, 2027266,477
__________
(1) Certain plans include shares to be sold solely to cover tax withholding obligations.
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Christine Fox [Member]  
Trading Arrangements, by Individual  
Name Christine Fox
Title EVP, U.S. Commercial
Rule 10b5-1 Arrangement Adopted true
Adoption Date August 4, 2026
Expiration Date November 21, 2026
Arrangement Duration 109 days
Aggregate Available 63,492
Matthew Shields [Member]  
Trading Arrangements, by Individual  
Name Matthew Shields
Title EVP, Teva Global Operations
Rule 10b5-1 Arrangement Adopted true
Adoption Date August 4, 2026
Expiration Date June 5, 2027
Arrangement Duration 305 days
Aggregate Available 171,410
Dr. Eric Hughes [Member]  
Trading Arrangements, by Individual  
Name Dr. Eric Hughes
Title EVP, Global R&D and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 1, 2026
Expiration Date March 8, 2027
Arrangement Duration 188 days
Aggregate Available 266,477